Abstract
Bckground: One of the major challenges of biopharmaceuticals having short plasma half-life is that daily high dose injections are needed which can lead to economic burden, patient inconvenience and undesirable side effects. Increasing the hydrodynamic volume beyond the pore size of the glomerular basal membrane is a viable approach to increase the size of small biopharmaceuticals with short half-life in blood circulation.
Objectives: PASylation technology is based on the genetic fusion of biopharmaceuticals with a hydrophilic random coil sequence of proline (Pro), alanine (Ala), and serine (Ser) amino acids.
Method: In this review, we focus on PASylation technology as a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals.
Results: PASylated biopharmaceuticals are suitable for the production in Escherichia coli (E.coli) as well as eukaryotic expression systems like yeast, HEK or CHO cells and comprise a homogeneous PAS sequence with exact length.We explain the general concept of PASylation, its development; advantages compared to other PK modifying technologies and describe furthermore the pharmacodynamic (PD) and PK properties of several PAS-fusion proteins in preclinical studies.
Conclusion: The biodegradable PAS sequence was already used for prolonging plasma half-life of clinical important agents such as antibody fragments, cytokines, enzymes and receptor-binding peptides.
Keywords: PASylation, tumor targeting, ESETEC technology, biodistribution, radiopharmaceutical, biopharmaceutical.
Current Drug Delivery
Title:PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals
Volume: 15 Issue: 3
Author(s): Sajjad Ahmadpour and Seyed Jalal Hosseinimehr*
Affiliation:
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: PASylation, tumor targeting, ESETEC technology, biodistribution, radiopharmaceutical, biopharmaceutical.
Abstract: Bckground: One of the major challenges of biopharmaceuticals having short plasma half-life is that daily high dose injections are needed which can lead to economic burden, patient inconvenience and undesirable side effects. Increasing the hydrodynamic volume beyond the pore size of the glomerular basal membrane is a viable approach to increase the size of small biopharmaceuticals with short half-life in blood circulation.
Objectives: PASylation technology is based on the genetic fusion of biopharmaceuticals with a hydrophilic random coil sequence of proline (Pro), alanine (Ala), and serine (Ser) amino acids.
Method: In this review, we focus on PASylation technology as a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals.
Results: PASylated biopharmaceuticals are suitable for the production in Escherichia coli (E.coli) as well as eukaryotic expression systems like yeast, HEK or CHO cells and comprise a homogeneous PAS sequence with exact length.We explain the general concept of PASylation, its development; advantages compared to other PK modifying technologies and describe furthermore the pharmacodynamic (PD) and PK properties of several PAS-fusion proteins in preclinical studies.
Conclusion: The biodegradable PAS sequence was already used for prolonging plasma half-life of clinical important agents such as antibody fragments, cytokines, enzymes and receptor-binding peptides.
Export Options
About this article
Cite this article as:
Ahmadpour Sajjad and Hosseinimehr Jalal Seyed *, PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals, Current Drug Delivery 2018; 15 (3) . https://dx.doi.org/10.2174/1567201814666171120122352
DOI https://dx.doi.org/10.2174/1567201814666171120122352 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry Utilizing Ultrasound to Transiently Increase Blood-Brain Barrier Permeability, Modulate of the Tight Junction Proteins, and Alter Cytoskeletal Structure
Current Neurovascular Research Models for the Study of Angiogenesis
Current Pharmaceutical Design AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Metal-dithiocarbamate complexes: chemistry and biological activity
Mini-Reviews in Medicinal Chemistry Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Protein Serine/Threonine Phosphotase-2A is Differentially Expressed and Regulates Eye Development in Vertebrates
Current Molecular Medicine Bioinformatic Analysis of HIV-1 Entry and Pathogenesis
Current HIV Research MD-LBP: An Efficient Computational Model for Protein Subcellular Localization from HeLa Cell Lines Using SVM
Current Bioinformatics Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Liposomes: Targeted and Controlled Delivery System
Drug Delivery Letters Behcets Syndrome: Literature Review
Current Rheumatology Reviews Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry Quantum Dot-Encoded Beads for Ultrasensitive Detection
Recent Patents on Nanotechnology Patent Selections
Recent Patents on DNA & Gene Sequences Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Personalized and Regenerative Medicine for Liver Diseases
Current Stem Cell Research & Therapy Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology